Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1994-2-15
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0954-6820
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
235
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1-4
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:8283155-Clinical Trials as Topic,
pubmed-meshheading:8283155-Coronary Disease,
pubmed-meshheading:8283155-Follow-Up Studies,
pubmed-meshheading:8283155-Gemfibrozil,
pubmed-meshheading:8283155-Humans,
pubmed-meshheading:8283155-Hyperlipidemias,
pubmed-meshheading:8283155-Survival Analysis
|
| pubmed:year |
1994
|
| pubmed:articleTitle |
Two follow-up studies of preventive lipid-lowering trials support the validity of the lipid hypothesis.
|
| pubmed:publicationType |
Editorial,
Comment
|